Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Treasury Shares (2023 - 2025)

Compass Therapeutics' Treasury Shares history spans 3 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Treasury Shares fell 72.7% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 72.7%, while the annual FY2025 figure was $1.0 million, 72.7% down from the prior year.
  • Treasury Shares for Q4 2025 was $1.0 million at Compass Therapeutics, down from $1.3 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.8 million in Q4 2024 and bottomed at $31000.0 in Q3 2023.
  • The 3-year median for Treasury Shares is $2.4 million (2023), against an average of $2.2 million.
  • The largest annual shift saw Treasury Shares soared 11725.81% in 2024 before it tumbled 72.7% in 2025.
  • A 3-year view of Treasury Shares shows it stood at $1.5 million in 2023, then surged by 151.07% to $3.8 million in 2024, then crashed by 72.7% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Treasury Shares are $1.0 million (Q4 2025), $1.3 million (Q3 2025), and $2.9 million (Q2 2025).